Injectable Drug Delivery Market Projected to Reach $1.14 Trillion by 2029 as Industry Leaders Convene for Innovation Summit
Key Insights
The injectable drug delivery market is projected to reach $1,139.4 billion by 2029, driven by complex biologics (search) and increased demand for patient self-administration.
Industry leaders from Pfizer, GSK, Sandoz, and other major pharmaceutical companies will gather at the Injectable Drug Delivery Conference in London on June 24-25, 2025.
The conference agenda focuses on critical challenges including subcutaneous delivery of biologics (search), large-volume injectables, and sustainable device development.
The injectable drug delivery market is experiencing unprecedented growth, with projections indicating it will reach $1,139.4 billion by 2029, according to industry data presented ahead of the Injectable Drug Delivery Conference scheduled for June 24-25, 2025, in London.
This rapid expansion is being driven by several key factors, including the increasing complexity of biologics (search), heightened demand for patient self-administration options, and advances in delivery technologies. The growth trajectory reflects the pharmaceutical industry's shift toward more sophisticated therapeutic modalities that require specialized delivery systems.
Industry Leaders Converge for Innovation Summit
The Injectable Drug Delivery Conference, organized by SAE Media Group, will bring together key players from the pharmaceutical and biotech community for two days of industry-leading insights and cross-sector collaboration. Rachel Koppelman, Head of Device Engineering at Sandoz and co-chair of the event, emphasized the conference's strategic value: "This is the perfect opportunity to benchmark your drug delivery programme and optimise the development of your injectable portfolio."
Confirmed attendees include experts from major pharmaceutical companies such as Pfizer, GSK, CSL Behring, Sanofi, Roche, Sandoz, UCB Medical Devices, West Pharmaceutical Services, and MedinCell. The diverse participant base spans senior leadership, R&D, packaging, device engineering, formulation, and regulatory affairs, ensuring a comprehensive networking environment.
Critical Challenges Take Center Stage
The 2025 agenda addresses the most urgent challenges and opportunities in injectable drug delivery, with particular focus on:
- Subcutaneous delivery of biologics and peptides
- Large-volume and long-acting injectables
- Sustainable device development and material sourcing
- Extractables/Leachables, biocompatibility, and toxicology
Expert-led case studies and panel debates will cover device design, materials science, regulatory strategy, and combination product development. Confirmed spotlight speakers include Joel Richard, Executive Head of Product Development at DBV Technologies; Conor O'Neill, Head of Packaging Development and Design at GSK; Chantal Pfaffen, Global Lead Material Qualification at CSL Behring; and Clovis Pichon, Head of Device Program Leadership at UCB Pharma.
Parallel Focus on Strategic Partnerships
Complementing the London conference, the 15th annual Partnership Opportunities in Drug Delivery (PODD) conference will take place October 27-28, 2025, at the Westin Copley Place in Boston. This event, organized by the Conference Forum, will spotlight strategic partnering in drug delivery innovation.
A key session titled "Partnering to Advance Drug Delivery Innovation" will be moderated by Ester Caffarel-Salvador, PhD, director of strategic innovation for rare diseases (search) at Chiesi USA (search). The panel will explore critical considerations for evaluating external drug delivery platforms, featuring perspectives from both early-stage and mature development environments.
Panelists include Sean Bedingfield, PhD, research & development advisor for Genetic Medicine at Eli Lilly and Company; Annette Bak, PhD, head of advanced drug delivery at AstraZeneca; Jaymin Shah, PhD, head of global biopharmaceutics and senior research fellow at Pfizer; and Rashmi Thakur, PhD, director of portfolio strategy & integration at Bristol-Myers Squibb (search).
Economic Considerations Drive Innovation Strategy
The PODD conference will also feature a dedicated session on "Payer Perspectives on Drug Delivery," exploring the intersection of innovation and reimbursement. This panel will assess how delivery systems influence value perception, pricing pressures, and market access, particularly for drug classes such as incretins (search) and nucleic acid-based therapies (search).
Representatives from Novartis and AbbVie (search) will offer insights into their organizations' approaches to sourcing and integrating drug delivery and enabling technologies. Mateja Kramer, PhD, global head of innovation at Novartis, and Nicholas Schill, PhD, senior director of landscaping & platform definition at AbbVie, will present as part of the conference's Pharma Company Spotlights.
Comprehensive Technology Coverage
The PODD 2025 agenda includes presentations across multiple drug delivery technology categories, including injectable formulations and delivery platforms, self-injection devices and wearables, oral and alternative non-injectable systems, cell and gene therapy delivery approaches, and innovations in excipients and combination product platforms.
Emerging topics will cover specialized approaches to delivery challenges in advanced modalities, including brain delivery mechanisms, novel vehicles for genetic medicine administration, ADCs and bioconjugation strategies, and tissue-specific targeting for nucleic acid therapeutics.
Andrew Goldstein, senior conference producer, noted that "PODD connects industry leaders and innovators who advance the design and development of drug delivery systems and devices to improve patient lives." The forum is designed to support scientific exchange and partnership building across traditional boundaries in the pharmaceutical sector.